A recently approved migraine treatment may start working right away, according to a study published in Neurology. Researchers tested atogepant, a calcitonin gene-related peptide receptor antagonist taken by mouth, and found that it reduced the frequency of migraines significantly.
In the study, participants taking atogepant had fewer migraines on the first day, during each week of the 12-week trial, and overall compared to those taking a placebo. The treatment also showed improvement in daily activities and quality of life.
The researchers focused on three trials with different patient groups: episodic migraine sufferers who had previously responded well or poorly to other treatments, and those with chronic migraines. People with episodic migraines experience up to 14 days of migraines per month, while those with chronic migraines experience at least 15 days.
While the study found positive results, it is essential to note that the participants were mostly female and white, which may limit the applicability of the findings to the broader population. Nonetheless, this new treatment offers hope for individuals suffering from migraine, particularly those who need quick relief.
Source: https://medicalxpress.com/news/2024-12-migraine-relief-drug.html